GE HealthCare Technologies (NASDAQ:GEHC) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS

GE HealthCare Technologies (NASDAQ:GEHC) released its quarterly earnings results on Wednesday. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.14, FiscalAI reports. GE HealthCare Technologies had a return on equity of 20.12% and a net margin of 9.33%. The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period last year, the firm posted $1.07 EPS. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year.

Here are the key takeaways from GE HealthCare Technologies’ conference call:

• GE HealthCare raised its full-year 2026 guidance, now expecting approximately 4% organic revenue growth, 15.5%–15.7% adjusted EBIT margin, adjusted EPS of $4.95–$5.05, and free cash flow above $1.6 billion.
• Third-quarter results exceeded expectations, with organic revenue up 6.2%, adjusted EBIT margin expanding 180 basis points to 16.6%, adjusted EPS rising 25.1% to $1.34, and free cash flow increasing to $793 million.
• Pharmaceutical Diagnostics delivered 13.8% organic growth, while Flyrcado adoption continued to build; management remains confident in its goal of reaching a $500 million annualized Flyrcado revenue run rate exiting 2028. The planned SOFIE Biosciences acquisition is intended to strengthen U.S. radiopharmaceutical distribution, manufacturing control, and the precision-medicine pipeline.
• Patient Care Solutions improved sharply, with organic revenue up 8.8% and margin expanding 480 basis points, but fourth-quarter growth will be muted by a difficult comparison related to a prior-year product-hold release. PCS leadership is changing, and GE HealthCare is still evaluating strategic options for the business, although management said the review timeline is unaffected.
• Management characterized capital-equipment demand and the imaging pipeline as resilient, with backlog up 12% year over year to $23.7 billion, but acknowledged ongoing risks from tariffs, inflation, oil prices, and elevated memory-chip costs. Multi-year supplier agreements are expected to improve component availability and reduce supply-chain volatility into 2027.

GE HealthCare Technologies Price Performance

NASDAQ:GEHC traded up $0.91 on Thursday, hitting $76.73. The company had a trading volume of 1,565,984 shares, compared to its average volume of 4,227,284. The firm has a 50 day moving average of $68.37 and a two-hundred day moving average of $70.17. The stock has a market capitalization of $34.66 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 1.89 and a beta of 0.73. GE HealthCare Technologies has a 52 week low of $58.75 and a 52 week high of $89.77. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.92.

GE HealthCare Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.0350. GE HealthCare Technologies’s payout ratio is currently 3.67%.

Analyst Ratings Changes

GEHC has been the subject of a number of recent research reports. Oppenheimer reissued an “outperform” rating on shares of GE HealthCare Technologies in a research report on Thursday, July 30th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of GE HealthCare Technologies in a report on Monday, October 5th. Needham & Company LLC reiterated a “buy” rating and issued a $93.00 price target on shares of GE HealthCare Technologies in a research report on Monday, October 5th. Weiss Ratings raised GE HealthCare Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, October 6th. Finally, Bank of America reissued a “neutral” rating on shares of GE HealthCare Technologies in a research report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.13.

Key Stories Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Third-quarter earnings and revenue beat expectations. GEHC reported adjusted EPS of $1.34, up from $1.07 a year earlier and above the roughly $1.20 consensus estimate. Revenue rose 7.2% year over year to $5.51 billion, exceeding expectations of about $5.35 billion. GE HealthCare reports third quarter 2026 financial results
• Positive Sentiment: Management raised its full-year outlook. GEHC increased its 2026 organic revenue growth forecast to 4%, raised adjusted EPS guidance to $4.95–$5.05, and expects at least $1.6 billion in free cash flow. The improved outlook reflects healthy hospital spending, strong segment growth, and margin expansion. GE HealthCare Lifts Forecasts on Healthy Hospital Spending
• Positive Sentiment: Growth opportunities are broadening. Analysts highlighted 6.2% organic growth, margin gains across segments, and potential from Pharmaceutical Diagnostics, Flyrcado, and the SOFIE acquisition, which should expand GEHC’s radiopharmaceutical capabilities and future revenue streams. GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling
• Positive Sentiment: Analyst sentiment improved. BTIG Research raised its price target from $75 to $83 and maintained a “buy” rating. BNP Paribas also lifted its target from $96 to $100, reinforcing the view that GEHC’s stronger execution could support additional upside. BNP Paribas Adjusts Price Target on GE HealthCare Technologies to $100 From $96
• Negative Sentiment: Leadership turnover is a potential concern. Jeannette Bankes, president and CEO of Patient Care Solutions, is leaving to become CEO of another company. The departure may create near-term execution and transition risk, although it was overshadowed by the earnings beat and guidance increase. GE HealthCare Announces Leadership Change in Patient Care Solutions

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company’s portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.